Ramucirumab plus paclitaxel for gastric cancer in China

MeSH terms

• Adenocarcinoma / diagnosis
• Adenocarcinoma / drug therapy
• Angiogenesis Inhibitors / administration & dosage
• Angiogenesis Inhibitors / therapeutic use
• Antibodies, Monoclonal, Humanized / administration & dosage
• Antibodies, Monoclonal, Humanized / therapeutic use*
• Antineoplastic Combined Chemotherapy Protocols / therapeutic use
• China / epidemiology
• Early Detection of Cancer / methods
• Esophagogastric Junction / pathology
• Humans
• Outcome Assessment, Health Care
• Paclitaxel / administration & dosage
• Paclitaxel / therapeutic use*
• Progression-Free Survival
• Protein Kinase Inhibitors / therapeutic use
• Pyridines / therapeutic use
• Ramucirumab
• Randomized Controlled Trials as Topic
• Stomach Neoplasms / drug therapy*
• Stomach Neoplasms / epidemiology
• Stomach Neoplasms / mortality
• Treatment Outcome
• Tubulin Modulators / administration & dosage
• Tubulin Modulators / therapeutic use
• Vascular Endothelial Growth Factor Receptor-2 / antagonists & inhibitors*